GlassScriptPhysician profile
Walter A Dimmitt
NPI 1467532267
$1,484.75
in general payments reported to CMS, 2019-2025
21 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.22 · 2020: $58.12 · 2021: $283 · 2022: $273 · 2023: $84.27 · 2024: $97.96 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $357.42 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $189.63 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $128.50 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $127.60 | 2020-2022 | |
| Amgen INC. | $90.06 | 2021-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $88.41 | 2019-2025 | Camzyos |
| Abbott Laboratories | $81.11 | 2022-2025 | Mitraclip |
| Bayer Healthcare Pharmaceuticals INC. | $61.51 | 2024-2025 | |
| Medtronic, INC. | $61.24 | 2022-2024 | In.Pact Admiral |
| Amarin Pharma, INC. | $54.92 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36.05 | 2023-2024 | Verquvo |
| Novo Nordisk INC | $32.30 | 2025 | Wegovy, Rybelsus, Ozempic |
| Actelion Pharmaceuticals US, INC. | $30.48 | 2025 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $24.36 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Daiichi Sankyo INC. | $23.65 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.17 | 2021 | |
| Esperion Therapeutics, INC. | $18.37 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $17.32 | 2022 | |
| Pfizer INC. | $15.56 | 2019 | |
| Lantheus Medical Imaging, INC. | $14.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Dimmitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.